- Synonyms
- Angie, B lymphocyte chemoattractant, CXC chemokine BLC, Small-inducible cytokine B13
- Source
- Escherichia coli.
- Molecular Weight
- Approximately 10.3 kDa, a single non-glycosylated polypeptide chain containing 87 amino acids.
- AA Sequence
- VLEVYYTSLR CRCVQESSVF IPRRFIDRIQ ILPRGNGCPR KEIIVWKKNK SIVCVDPQAE WIQRMMEVLR KRSSSTLPVP VFKRKIP
- Purity
- > 97 % by SDS-PAGE and HPLC analyses.
- Biological Activity
- Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human B cells is in a concentration range of 1.0-10 ng/ml.
- Physical Appearance
- Sterile Filtered White lyophilized (freeze-dried) powder.
- Formulation
- Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 100 mM NaCl.
- Endotoxin
- Less than 1 EU/μg of rHuBCA-1/CXCL13 as determined by LAL method.
- Reconstitution
- We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
- Stability & Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
- Usage
- This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
- Reference
- 1. Legler DF, Loetscher M, Roos RS, et al. 1998. J Exp Med. 187:655-60.
2. Gunn MD, Ngo VN, Ansel KM, et al. 1998. Nature. 391:799-803.
3. Ansel KM, Harris RB, Cyster JG. 2002. Immunity. 16:67-76.
4. Ansel KM, Ngo VN, Hyman PL, et al. 2000. Nature. 406:309-14.
- Background
- C-X-C motif chemokine 13 encoded by the CXCL13 gene located on human chromosome 4 is constitutively expressed in secondary lymphoid organs. It is also known as B lymphocyte chemoattractant (BLC). As its name suggests, CXCL13 is selectively chemotactic for B cells belonging to both the B-1 and B-2 subsets, and elicits its effects by interacting with chemokine receptor CXCR5. It and its receptor CXCR5 control the organization of B cells within follicles of lymphoid tissues. Recombinant human CXCL13 is a single non-glycosylated polypeptide chain containing 87 amino acids and mature human BCA-1 shares 64 % amino acid sequence similarity with the murine protein and 23–34 % amino acid sequence identity with other known CXC chemokines.